{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-066416","form_type":"8-K","ticker":"ARTV","cik":"0001817241","company_name":"Artiva Biotherapeutics, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.853972+00:00","generated_at":"2026-05-22T05:17:51.783432+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Artiva reports Q1 net loss $20.3M; AlloNK IND cleared for autoimmune basket trial","bullets":["Cash, cash equivalents and investments of $166.0M as of March 31, 2025; cash runway into Q2 2027.","R&D expenses $17.1M (vs $11.2M YoY); net loss $20.3M (vs $14.0M YoY).","IND cleared for Phase 2a basket trial of AlloNK+rituximab in refractory RA, Sjögren's, myositis, scleroderma; site initiation underway.","Longer-term B-NHL data at ASGCT shows CR rates and median DOR in line with approved auto-CAR-T therapies.","Appointed Subhashis Banerjee, M.D. as CMO on April 8, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-066416","json":"https://secwatch.observer/filing/0000950170-25-066416.json","markdown":"https://secwatch.observer/filing/0000950170-25-066416.md","text":"https://secwatch.observer/filing/0000950170-25-066416.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817241/000095017025066416/0000950170-25-066416-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817241/000095017025066416/artv-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:17:51.783432+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}